4//SEC Filing
Auspex Pharmaceuticals, Inc. 4
Accession 0001209191-15-039548
CIK 0001454189operating
Filed
May 5, 8:00 PM ET
Accepted
May 6, 6:10 PM ET
Size
5.8 KB
Accession
0001209191-15-039548
Insider Transaction Report
Form 4
Bleil Lynn Dorsey
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2015-05-05−20,000→ 0 totalExercise: $18.13Exp: 2024-05-05→ Common Stock (20,000 underlying)
Footnotes (1)
- [F1]Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated March 29, 2015, among the Issuer, Teva Pharmaceuticals Industries Ltd. ("Parent"), and Aurum Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), under the terms of which Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation (the "Merger"), this option, which is fully vested, was cancelled in the Merger in exchange for a cash payment equal to $101.00 per share (without interest) minus the per share exercise price of the option.
Documents
Issuer
Auspex Pharmaceuticals, Inc.
CIK 0001454189
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001454189
Filing Metadata
- Form type
- 4
- Filed
- May 5, 8:00 PM ET
- Accepted
- May 6, 6:10 PM ET
- Size
- 5.8 KB